

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: Koios Beverage Corp. (the “Issuer”).

Trading Symbol: KBEV

Number of Outstanding Listed Securities: 87,834,675 common shares were issued and outstanding as of March 31, 2021

Date: April 7, 2021 (for the month of March 2021)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer, through its wholly-owned subsidiary Koios, Inc. ("Koios"), is an emerging functional beverage company which has an available distribution network of more than 4,400 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including GNC, Walmart Inc., and Wishing-U-Well. Together these retailers represent over 50,000 brick and mortar locations across the United States from sports nutrition stores to large natural grocery chains. Through its partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product. Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants. Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity. Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.

The Issuer continues to seek opportunities to expand its brand and increase distribution in Canada and the United States.

2. Provide a general overview and discussion of the activities of management.

During the month of March 2021, management's principal activities consisted of:

- entering into a distribution agreement with NewAge, Inc., a major omnichannel wholesaler of beverages and snacks;
- announcing that all five flavours of its KOIOS™ nootropic beverage and all four flavours of its Fit Soda™ will be carried in select Texas locations of Drug Emporium, a "big box" pharmacy chain with stores in Texas, Arkansas and Louisiana;
- announcing that its KOIOS™ nootropic beverages and Fit Soda™ functional beverages have been approved for placement at Sprouts Farmers Market who has more than 360 stores in 23 states. With the addition of Sprouts, the brand will now be carried in more than 4,200 stores across various regions of the United States;
- closing a non-brokered private placement of 45,000,000 warrants ("Warrants") at a price of \$0.02 per Warrant for gross proceeds of \$900,000. Each Warrant entitles the holder to acquire one unit of the Company (each a "Unit"). Each Unit consists of one common share in the capital of the Company (each, a "Share") and one transferable common share purchase warrant (each, a "Conversion Warrant"). Each Warrant will

entitle the holder thereof to acquire one Unit at a price of \$0.03 per Unit for a period of two years from closing. Each Conversion Warrant will entitle the holder thereof to acquire one additional Share at a price of \$0.05 per Share until 5:00 p.m. (Vancouver time) on the date of expiration of the Conversion Warrant, which is two years following the closing date; and

- general management and administrative matters.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

During the month of March 2021, the Issuer announced that it has entered into a distribution agreement with NewAge, Inc., a major omnichannel wholesaler of beverages and snacks. Based in Denver Colorado, NewAge provides direct store delivery service for beverage brands all across the state of Colorado, primarily in the Front Range region. NewAge will distribute all of Koios' beverage products including KOIOS™ nootropic beverages and Fit Soda™ functional beverages.

The Issuer also announced that all five flavours of its KOIOS™ nootropic beverage and all four flavours of its Fit Soda™ functional beverage will be carried in select Texas locations of Drug Emporium, a "big box" pharmacy chain with stores in Texas, Arkansas and Louisiana.

The Issuer also announced that its KOIOS™ nootropic beverages and Fit Soda™ functional beverages have been approved for placement at Sprouts Farmers Market who has more than 360 stores in 23 states. With the addition of Sprouts, the brand will now be carried in more than 4,200 stores across various regions of the United States.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of March 2021.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

During the month of March 2021, the Issuer announced that it has entered into a distribution agreement with NewAge, Inc., a major omnichannel wholesaler of beverages and snacks. Based in Denver Colorado, NewAge provides direct store delivery ("DSD") service for beverage brands all across the state of Colorado, primarily in the Front Range region. NewAge will distribute all of Koios' beverage

products including KOIOS™ nootropic beverages and Fit Soda™ functional beverages.

The Issuer announced that all five flavours of its KOIOS™ nootropic beverage and all four flavours of its Fit Soda™ functional beverage will be carried in select Texas locations of Drug Emporium, a “big box” pharmacy chain with stores in Texas, Arkansas and Louisiana.

The Issuer announced that its KOIOS™ nootropic beverages and Fit Soda™ functional beverages have been approved for placement at Sprouts Farmers Market who has more than 360 stores in 23 states. With the addition of Sprouts, the brand will now be carried in more than 4,200 stores across various regions of the United States.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no contracts or agreements between the Issuer, the Issuer’s affiliates or third parties that terminated or expired and there weren’t any previously announced financing arrangements that terminated during the month of March 2021.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no asset acquisitions or dispositions by the Issuer during the preceding month of February 2021.

8. Describe the acquisition of new customers or loss of customers.

Please see item 5 above for a summary of new locations that will carry Koios Beverages thus increasing the Issuer’s ability to attract new customer.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks during the month of March 2021.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of March 2021.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of March 2021.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became party to during the month of March 2021.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no indebtedness incurred or repaid by the Issuer during the month of March 2021.

14. Provide details of any securities issued and options or warrants granted.

During the month of March 2021, the following securities were issued:

Security	Number Issued	Details of Issuance	Use of Proceeds
Common shares	6,608,075	Exercise of various warrants and stock options	Proceeds received from the exercise of warrants will be used for general working capital.
Warrants	45,000,000	Private Placement	Proceeds received from Private Placement will be used for marketing, development of its products, investor relations activity, and for general working capital

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons of the Issuer during the month of March 2021.

16. Provide details of any changes in directors, officers or committee members.

As at the date of this report, the directors and officers of the Issuer are as follows:

Erik LeVang	Director
Sherron Lewis	Director
Josh Luman	Director
Christopher Miller	Director, Chief Executive Officer and Interim Corporate Secretary
Johannes (Theo) van der Linde	Chief Financial Officer

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's MD&A for the interim period ended November 30, 2020 dated as of January 29, 2021, available on the Issuer's SEDAR profile at [www.sedar.com](http://www.sedar.com).

In addition to the trends and risks detailed in the MD&A, COVID-19 is likely to impact the Issuer:

### **COVID-19**

The outbreak of the corona virus pandemic has impacted the Issuer's plans and activities. The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases represent a serious threat to maintaining a skilled workforce industry and could be a major health-care challenge for the Issuer. There can be no assurance that the Issuer's personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures and business disruptions, can all have an impact on the Issuer's operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that may be brought about by the COVID-19 pandemic on global financial markets may reduce resource prices, share prices and financial liquidity and thereby that may severely limit the financing capital available.

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 7, 2021.

Christopher Miller  
Name of Director or Senior Officer

"Chris Miller"  
Signature

Chief Executive Officer  
Official Capacity

<b>Issuer Details</b>	For Month End	Date of Report
Name of Issuer Koios Beverage Corp.	March 2021	YY/MM/D 2021/04/07
Issuer Address Suite 810 – 789 West Pender Street		
City/Province/Postal Code Vancouver, BC V6C 1H2	Issuer Fax No. (604) 687-3141	Issuer Telephone No. (604) 687-2038
Contact Name Christopher Miller	Contact Position CEO	Contact Telephone No. (303) 946-2728
Contact Email Address Chris@koiosbeveragecorp.com	Web Site Address <a href="https://koiosbeveragecorp.com">https://koiosbeveragecorp.com</a>	